{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:09Z","timestamp":1790223429485,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clinre.2022.101869","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T08:27:45Z","timestamp":1643617665000},"page":"101869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8637-7498","authenticated-orcid":false,"given":"Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.101869_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinre.2022.101869_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinre.2022.101869_bib0003","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinre.2022.101869_bib0004","unstructured":"Organaization WH. World Health Organaization. 2018. http:\/\/gco.iarc.fr\/today\/fact-sheets-populations."},{"key":"10.1016\/j.clinre.2022.101869_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MCG.0b013e3181d46ef2","article-title":"Hepatocellular carcinoma (HCC): a global perspective","volume":"44","author":"Ferenci","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinre.2022.101869_bib0006","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2188\/jea.JE20100190","article-title":"Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures","volume":"21","author":"Tanaka","year":"2011","journal-title":"J Epidemiol"},{"key":"10.1016\/j.clinre.2022.101869_bib0007","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000488035","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)","volume":"7","author":"Zhou","year":"2018","journal-title":"Liver Cancer"},{"key":"10.1016\/j.clinre.2022.101869_bib0008","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11604-012-0088-1","article-title":"Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis?","volume":"30","author":"Yamakado","year":"2012","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.clinre.2022.101869_bib0009","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2022.101869_bib0010","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2022.101869_bib0011","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinre.2022.101869_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.607520","article-title":"Advanced hepatocellular carcinoma with hepatic arterioportal shunts: combination treatment of transarterial chemoembolization with apatinib","volume":"7","author":"Sun","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.clinre.2022.101869_bib0013","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.21037\/atm-20-7244","article-title":"Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma","volume":"8","author":"Gu","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinre.2022.101869_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215430","article-title":"Locoregional therapies for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"13","author":"Zane","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinre.2022.101869_bib0015","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1007\/s00330-017-5145-9","article-title":"Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"28","author":"Choi","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clinre.2022.101869_bib0016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.diii.2016.06.002","article-title":"Obesity conveys poor outcome in patients with hepatocellular carcinoma treated by transarterial chemoembolization","volume":"98","author":"Wu","year":"2017","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.clinre.2022.101869_bib0017","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4103\/jcrt.JCRT_801_19","article-title":"Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: a propensity score matching analysis","volume":"16","author":"Shen","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.clinre.2022.101869_bib0018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3389\/fonc.2020.00970","article-title":"Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: a propensity score matching analysis","volume":"10","author":"Kan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2022.101869_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5565793","article-title":"Efficacy and safety of the arsenic trioxide\/lipiodol emulsion in the transcatheter arterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma","volume":"2021","author":"Li","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2022.101869_bib0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13046-018-1005-y","article-title":"Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3eta\/NF-kappaB feedback loop","volume":"37","author":"Qiu","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clinre.2022.101869_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10637-006-9004-9","article-title":"Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial","volume":"25","author":"Lin","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinre.2022.101869_bib0022","article-title":"Portal vein stenting combined with (125)I particle chain implantation followed by As2O3 in the treatment of hepatocellular carcinoma with portal vein tumour thrombus","volume":"2020","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clinre.2022.101869_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.toxlet.2014.08.024","article-title":"Inhibition of TGF-beta\/SMAD3\/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells","volume":"231","author":"Jiang","year":"2014","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.clinre.2022.101869_bib0024","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/toxsci\/kfu218","article-title":"Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal","volume":"143","author":"Li","year":"2015","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.clinre.2022.101869_bib0025","article-title":"Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value","author":"Liu","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clinre.2022.101869_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5144\/1658-3876.2011.60","article-title":"Arsenic trioxide plus cisplatin\/interferon alpha-2b\/doxorubicin\/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma","volume":"4","author":"Tomuleasa","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.clinre.2022.101869_bib0027","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-7-28","article-title":"Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model","volume":"7","author":"Zhang","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinre.2022.101869_bib0028","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/cncr.29456","article-title":"Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clinre.2022.101869_bib0029","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.2147\/CMAR.S304591","article-title":"Evaluation of the benefits of TACE combined with sorafenib for hepatocellular carcinoma based on untreatable TACE (unTACEable) progression","volume":"13","author":"Zou","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clinre.2022.101869_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.673378","article-title":"Sorafenib versus apatinib both combined transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a comparative retrospective study","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinre.2022.101869_bib0031","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpharm.2018.09.043","article-title":"A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors","volume":"552","author":"Liu","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinre.2022.101869_bib0032","doi-asserted-by":"crossref","first-page":"L990","DOI":"10.1152\/ajplung.00436.2020","article-title":"VEGF\/Src signaling mediated pleural barrier damage and increased permeability contributes to subpleural pulmonary fibrosis","volume":"320","author":"Lu","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.clinre.2022.101869_bib0033","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/10641963.2021.1937202","article-title":"Association between endothelial nitric oxide synthase and the renin-angiotensin-aldosterone system polymorphisms, blood pressure and training status in normotensive\/pre-hypertension and hypertensive older adults: a pilot study","volume":"43","author":"Silva","year":"2021","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.clinre.2022.101869_bib0034","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/CIRCRESAHA.108.178467","article-title":"An ezrin\/calpain\/PI3K\/AMPK\/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production","volume":"104","author":"Youn","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.clinre.2022.101869_bib0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/path.3964","article-title":"Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability","volume":"226","author":"Salmon","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.clinre.2022.101869_bib0036","doi-asserted-by":"crossref","first-page":"F747","DOI":"10.1152\/ajprenal.00617.2017","article-title":"VEGF therapy for the kidney: emerging strategies","volume":"315","author":"Guise","year":"2018","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:30Z","timestamp":1761895950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2210740122000122"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101869","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101869"}}